Economy

Impax Labs Inc (IPXL) Has Stock More Room to Run

WWE's SI was 5.13 million shares in October as released by FINRA. Its up 23.4% from 4,700 shares previously.

He added: "While the new company may be a good longer-term deal, in the near term it's clearly dilutive to Impax's equity value as the stock is trading down from the $20-$23 range over the past few months". World Wrestling Entertainment, Inc. HemaCare Corporation (OTCMKTS:HEMA) has 0.00% since October 18, 2016 and is. It has underperformed by 0.78% the S&P500. 2 analysts say it's a Hold while 0 analysts provided their expert opinion as Sell. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

Taking a broader look at the analyst consensus, according to 13 analysts Impax Labs Inc (NASDAQ:IPXL)'s price will reach at $19.23 during 52 weeks. The Volatility 12m of Impax Laboratories, Inc. After this sale, 112,166 common shares of IPXL are directly owned by the insider, with total stake valued at $2,405,961.

Canaccord Genuity for instance, initiated the stock on 31/07/2017 whilst Piper Jaffray issued a upgraded the stock on 18/07/2017. The consensus recommendation for stock is 3.00.

How has the stock performed recently? BTIG Research initiated it with "Buy" rating and $48 target in Tuesday, October 6 report. The firm has "Hold" rating given on Wednesday, August 9 by Cowen & Co. As per Tuesday, July 19, the company rating was initiated by Janney Capital. Share performance for the month is now at -8.10%.

Impax Laboratories (NASDAQ:IPXL) last posted its quarterly earnings results on Wednesday, August 9th.

Analysts await Impax Laboratories Inc (NASDAQ:IPXL) to report earnings on November, 8. For the quarter, shares have been noted at 11.27%. The company's forward price to earnings ratio for next fiscal year is 18.28. The quarterly performance for the stock is 9.35%, while the half-yearly performance is 53.78%.

Impax Laboratories, Inc.is a specialty pharmaceutical company. The company has market cap of $1.25 billion. The Company is involved in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It now has negative earnings. Its segments include Impax Generics and Impax Specialty Pharma.

Investors sentiment decreased to 0.9 in 2017 Q2. Its down 0.40, from 1.3 in 2017Q1.

Analyst research firms are expressing bullish stance on Impax Laboratories, Inc. Icon Advisers Incorporated reported 0.03% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL). The ERP5 of Impax Laboratories, Inc. It has a return on equity (ROE) of -0.10%. The insider now directly owns 30,733 shares worth $659,223. (NASDAQ:IPXL) shares have recently been behaving interestingly to keep investors awake.

Impax Laboratories, Inc. (NASDAQ:IPXL) in the last month has decreased -7.88%. Morgan Stanley stated it has 0% of its portfolio in Impax Laboratories Inc (NASDAQ:IPXL). 0 analysts gave its stock an Outperform rating. Goldman Sachs Group, Inc. On Friday, May 12 the insider NESTOR MICHAEL sold $11,977. Meeder Asset Mgmt Inc invested in 655 shares. 22 funds opened positions while 71 raised stakes. A sudden increase in a stock's activity can be a sign that investors are trading in anticipation of a catalyst, or that investors feel very strongly in one way or the other about the future direction of a stock. Schwab Charles Inc reported 0.01% stake. (NYSE:MNR) for 220 shares. Scout Invs invested in 0.04% or 95,275 shares. Trexquant Investment Lp accumulated 49,425 shares. Voya Mngmt Limited Co accumulated 0% or 16,755 shares. Parametric Associate Ltd holds 0% or 127,259 shares in its portfolio. State Street Corp has 1.62M shares. The Mean Recommendation is the average rating on a stock by the analyst community. Therefore 40% are positive. The firm earned "Neutral" rating on Thursday, December 1 by DA Davidson. (NYSE:MNR) has risen 27.78% since October 19, 2016 and is uptrending. The rating was downgraded by BMO Capital Markets on Friday, December 2 to "Market Perform". The firm has "Buy" rating by M Partners given on Tuesday, January 10. Cantor Fitzgerald restated a buy rating and issued a $25.00 target price on shares of Impax Laboratories in a report on Monday, September 25th. The company maintains price to book ratio of 2.64.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.



Like this

loading...
loading...

Latest


20 October 2017
Las Vegas hotel guard describes being shot by Paddock
Campos said that during the shooting, a woman came out of her hotel room and he told her to go back inside because it wasn't safe. He decided not to say he was hit in order to free up radio traffic to allow security to coordinate the response.

20 October 2017
Stitch Fix files for IPO, testing investor appetite for online retailers
Based on that, along with guidance from a flesh and blood stylist, Stitch Fix then sends five items, clothing and accessories. Customers can ship back whatever they don't like or they'll be charged for anything they keep, minus the $20 fee.

20 October 2017
Detroit Tigers reportedly select Ron Gardenhire as next manager
Arguably the most important decision that Detroit Tigers general manager Al Avila faced this offseason was hiring a new manager. He certainly knows the division, having managed in Minnesota from 2002-14, including winning AL Manager of the Year in 2010.

20 October 2017
Lloyds investors 'mugged' by deal
Lloyds shareholders allege the subsequent government-brokered takeover of HBOS , that valued the struggling bank at around 5.9 billion pounds, wiped billions off the bank's market value.

20 October 2017
Will Umpqua Holdings Corporation's (UMPQ) Earnings Grow In The Year Ahead?
On October 18, 2017, Umpqua Holdings Corporation issued a press release announcing third quarter 2017 financial results. The bank reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.27 by ($0.01).

20 October 2017
Potash Corporation of Saskatchewan Inc (POT) Analysts See $0.15 EPS
Watching the signals on shares of Potash Corp. of Saskatchewan Inc ( POT ), we note that the PPO is now below the signal line. Cowen & Co downgraded Potash Corporation of Saskatchewan ( USA ) (NYSE: POT ) on Thursday, April 14 to "Underperform" rating.

20 October 2017
Alonso to race on with McLaren in 2018
While he couldn't speak on any particulars, the contract is believed to be for one year with an option to extend, per the BBC . Formula One F1 - Japanese Grand Prix 2017 - Suzuka Circuit, Japan - October 5, 2017.

20 October 2017
Be informed: Breast Cancer Awareness
Caring for you is a lifelong responsibility and breast health is one very important part, especially for women. She has shared some facts that both women and men should know this month.

20 October 2017
Iran's Revolutionary Guards to accelerate ballistic missile project despite USA pressure
Tehran has repeatedly pledged to continue what it calls a defensive missile capability in defiance of Western criticism. The Trump administration has imposed new unilateral sanctions targeting Iran's missile activity.

19 October 2017
Revenue Estimates Analysis Of Abercrombie & Fitch Co. (ANF)
More recent Abercrombie & Fitch Co. 184.16 million shares or 4.32% less from 192.47 million shares in 2017Q1 were reported. The firm has "Sector Perform" rating given on Wednesday, August 31 by RBC Capital Markets. (NYSE:ANF) for 517,187 shares.